Market Overview

UPDATE: Goldman Sachs Lowers PT on Infinity Pharmaceuticals on Multiple Negative Factors

Related INFI
10 Stocks That Rallied Three Days On Increasing Volume
10 Stocks That Plummeted The Past Three Days On Increasing Volume

In a report published Friday, Goldman Sachs analyst Navdeep Singh reiterated a Neutral rating on Infinity Pharmaceuticals (NASDAQ: INFI), but lowered the price target from $40.00 to $20.00.

In the report, Goldman Sachs noted, “We are lowering our 12-month price target for INFI to $20 (from $40) due to (1) increased competitive pressure from GILD's idelalisib, (2) uncertainty on IPI-145's (oral therapy for blood cancers) safety profile, and (3) lack of visibility on commercial positioning. We now project IPI-145 peak sales of $1bn (from $2.8bn) and assign no success (from a 20% probability of success) to retaspimycin (HSP-90 inhibitor for lung cancer) due to mixed competitor data at ASCO. We maintain our Neutral rating on INFI and look for more clarity at ASH when updated IPI-145 data is expected. For more details see our slide deck.”

Infinity Pharmaceuticals closed on Wednesday at $16.46.

Latest Ratings for INFI

Jun 2016William BlairDowngradesOutperformMarket Perform
Jun 2016JefferiesDowngradesBuyHold
Jun 2016Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Navdeep SinghAnalyst Color Price Target Analyst Ratings


Related Articles (INFI)

View Comments and Join the Discussion!